Nafithromycin: India Launches First Locally Developed Antibiotic

November 28, 2024

Wockhardt Ltd has developed Nafithromycin, the first domestically produced antibiotic targeting multi-drug-resistant bacteria. This antibiotic is aimed at treating community-acquired bacterial pneumonia (CABP) in adults, the launch was held on November 20, 2024, in New Delhi. The event was organized by the Department of Biotechnology and BIRAC. Dr. Jitendra Singh, the Union Minister of State for Science and Technology, was present.

Global Health Impact

Pneumonia caused by drug-resistant bacteria poses a serious global health threat, which accounts for over two million deaths annually. India has 23% of the world’s pneumonia cases. The country faces increasing resistance to existing antibiotics, such as azithromycin. Nafithromycin emerges as a new solution to combat this issue.

Development Support

BIRAC provided Rs 8 crore in support for the project. The total cost for clinical trials was Rs 500 crore. Trials were conducted in the United States, Europe, and India. This backing was crucial for the successful development of Nafithromycin.

Drug Efficacy

Nafithromycin is a groundbreaking antibiotic for respiratory infections, which is the first new antibiotic in 30 years. The drug is taken as a single tablet daily for three days. It is ten times more potent than azithromycin and has eight times better lung absorption. The clinical cure rate stands at 96.7%, and it is safe for patients.

Research Timeline

The development of Nafithromycin took 14 years of extensive research. Dr. Jitendra Singh brought into light its importance in fighting antimicrobial resistance (AMR). AMR occurs when bacteria become resistant to medications, complicating treatment.

Large pharmaceutical companies have reduced antibiotic development efforts. This gap has allowed smaller firms like Wockhardt to innovate. Discussions hosted by the Centre for Science and Environment explored challenges faced by Indian antibiotic developers. These conversations aim to encourage future innovations in antibiotic development.

Important Facts for Exams:
BIRAC: The Biotechnology Industry Research Assistance Council supports biotechnological innovations in India. It provides funding and guidance for projects, enhancing research and development in the biotechnology sector.
AMR: Antimicrobial resistance occurs when bacteria evolve to resist medications. This complicates treatment options, leading to increased morbidity and mortality rates, making it global health concern.
CABP: Community-acquired bacterial pneumonia is an infection acquired outside of healthcare settings. It poses serious health risks, particularly among adults, and is often caused by drug-resistant bacteria.

« Previous Post Next Post »